论文部分内容阅读
目的探讨中西医结合治疗小细胞肺癌(SCLC)化疗患者的临床疗效。方法选取2012年3月—2014年3月陕西省核工业二一五医院呼吸科收治的SCLC患者120例,采用随机数字表法分为观察组和对照组各60例。两组患者均采用EP〔顺铂(DDP)+足叶乙甙(VP-16)〕或CE〔卡铂(CBP)+VP-16〕化疗方案,化疗期间两组患者均给予对症和支持治疗,21 d为1个周期,共进行2个周期。观察组患者于化疗前1周开始静脉滴注参芪扶正注射液,直至化疗结束。比较两组患者的临床疗效和预后情况。结果观察组患者的临床疗效优于对照组(P<0.05)。观察组患者的骨髓抑制和胃肠道反应分级优于对照组(P<0.05)。观察组患者的卡氏(KPS)评分分布情况优于对照组,5年生存率高于对照组(P<0.05)。结论中西医结合治疗SCLC的临床疗效确切,不良反应较少,且患者预后较好。
Objective To investigate the clinical efficacy of integrated traditional Chinese and western medicine in the treatment of patients with small cell lung cancer (SCLC) chemotherapy. Methods From March 2012 to March 2014, 120 cases of SCLC patients admitted to the Department of Respiratory, 215 Hospital of Nuclear Industry, Shaanxi Province were divided into observation group (60 cases) and control group (60 cases) by random number table. Patients in both groups were treated with EP (DDP) + etoposide (VP-16) or CE [carboplatin (CBP) + VP-16] chemotherapy. Both groups were given symptomatic and supportive care , 21 d for a cycle, a total of 2 cycles. Patients in the observation group started intravenous infusion of Shenqi Fuzheng Injection one week before chemotherapy until the end of chemotherapy. The clinical efficacy and prognosis of the two groups were compared. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). The bone marrow suppression and gastrointestinal reaction grade in the observation group were better than those in the control group (P <0.05). The distribution of KPS score in observation group was better than that in control group, and the 5-year survival rate was higher than that in control group (P <0.05). Conclusion The clinical efficacy of integrated traditional Chinese and western medicine in the treatment of SCLC is accurate, with fewer adverse reactions and better prognosis.